Patents by Inventor Maximilian von EYNATTEN

Maximilian von EYNATTEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210228610
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: November 10, 2020
    Publication date: July 29, 2021
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • MEDICAL USE OF PHARMACEUTICAL COMBINATION OR COMPOSITION
    Publication number: 20210205315
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: March 23, 2021
    Publication date: July 8, 2021
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20210205316
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: March 23, 2021
    Publication date: July 8, 2021
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200368261
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: February 28, 2020
    Publication date: November 26, 2020
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200360412
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: February 20, 2020
    Publication date: November 19, 2020
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20200338086
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200268777
    Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.
    Type: Application
    Filed: November 26, 2019
    Publication date: August 27, 2020
    Inventors: Uli Christian BROEDL, Maximilian von EYNATTEN, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd Roland LUIPPOLD
  • Medical use of pharmaceutical combination or composition
    Publication number: 20200171038
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 4, 2020
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200138844
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: January 9, 2020
    Publication date: May 7, 2020
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200138770
    Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
    Type: Application
    Filed: January 9, 2020
    Publication date: May 7, 2020
    Inventors: Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen WOERLE
  • CARDIO- AND RENOSAFE ANTIDIABETIC THERAPY
    Publication number: 20200022985
    Abstract: The present invention relates to cardio- and renosafe antidiabetic therapy.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 23, 2020
    Inventors: Maximilian VON EYNATTEN, Odd-Erik JOHANSEN
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190350957
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Application
    Filed: February 28, 2019
    Publication date: November 21, 2019
    Inventors: Uli Christian BROEDL, Sreeraj MACHA, Maximilian von EYNATTEN, Hans-Juergen WOERLE
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20190192523
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190134072
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: September 14, 2018
    Publication date: May 9, 2019
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 10258637
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: April 16, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
    Publication number: 20190099427
    Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 4, 2019
    Inventors: Thomas KLEIN, Maximilian von EYNATTEN, Michael MARK
  • MEDICAL USE OF PHARMACEUTICAL COMBINATION OR COMPOSITION
    Publication number: 20190060320
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 28, 2019
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190038654
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 7, 2019
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
    Patent number: 10195203
    Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 5, 2019
    Assignee: Boehringr Ingelheim International GmbH
    Inventors: Thomas Klein, Maximilian von Eynatten, Michael Mark
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190015437
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: March 12, 2018
    Publication date: January 17, 2019
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel